OFI Invest Asset Management Sells 2,790,848 Shares of Axon Enterprise, Inc $AXON

Key Points

• OFI Invest cut its stake in Axon by 99.7% in Q4, selling 2,790,848 shares and leaving it with 9,310 shares worth about $5.29 million, according to an SEC filing.
• Axon unveiled new AI products (Axon Vision, expanded Axon Assistant, Axon 911) aimed at boosting real-time public-safety data and multi-year growth, and while some banks trimmed price targets, analysts remain largely constructive with a consensus rating of Moderate Buy and a target of ~$755.88.

OFI Invest Asset Management trimmed its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 99.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,310 shares of the biotechnology company's stock after selling 2,790,848 shares during the quarter. OFI Invest Asset Management's holdings in Axon Enterprise were worth $5,287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. NEOS Investment Management LLC lifted its position in Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company's stock worth $18,206,000 after purchasing an additional 11,482 shares during the period. Vanguard Group Inc. lifted its position in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company's stock worth $132,349,000 after purchasing an additional 5,953 shares during the period. Legal & General Group Plc raised its stake in Axon Enterprise by 3.1% during the third quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company's stock worth $302,208,000 after acquiring an additional 12,736 shares in the last quarter. Finally, BIT Capital GmbH raised its stake in Axon Enterprise by 75.6% during the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company's stock worth $2,537,000 after acquiring an additional 1,522 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Wall Street reaffirmations and bullish notes tied to Axon Week and new AI products have supported the stock recently; several analysts reiterated buy ratings and highlighted AI-driven growth as a reason to view the pullback as a buying opportunity. Why Axon Stock Bounced Back After Falling 10%
• Positive Sentiment: Axon unveiled new AI offerings (Axon Vision, expanded Axon Assistant, Axon 911) at its annual conference intended to boost real-time public-safety data capabilities — a product roadmap that analysts say could drive multi-year revenue and margin improvement. Can Axon’s New AI Suite Reframe Its Real-Time Data Advantage Story for Investors (AXON)?
• Neutral Sentiment: Analysts trimmed price targets (Goldman Sachs and TD Cowen cut targets) but largely maintained constructive ratings — this reduces upside in the near term while leaving longer-term bull cases intact. Goldman Sachs price target update
• Neutral Sentiment: Sector/market news (e.g., coverage of peers and ad-tech moves) may be pulling investor attention and flows away from defensible growth stories, but these items are indirect for Axon. Macquarie sees AppLovin’s e-commerce push as a multi-year growth driver
• Negative Sentiment: New legal risk headlines tied to the company’s HQ and the cumulative effect of price-target cuts triggered fresh selling pressure; those headlines were cited by market coverage as a primary reason shares moved lower. Why Axon (AXON) Shares Are Trading Lower Today
• Negative Sentiment: Today’s decline was compounded by momentum selling and elevated volume after yesterday’s drop; market commentary and drop reports amplified the move. Axon Enterprise (AXON) Stock Drops Despite Market Gains

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $351.33 on Friday. Axon Enterprise, Inc has a twelve month low of $347.28 and a twelve month high of $885.91. The firm has a market cap of $28.25 billion, a PE ratio of 231.14, a price-to-earnings-growth ratio of 8.36 and a beta of 1.61. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The business has a fifty day moving average of $467.16 and a 200-day moving average of $569.82.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. During the same period last year, the company posted $2.08 earnings per share. The firm's quarterly revenue was up 38.5% compared to the same quarter last year. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the subject of several recent analyst reports. UBS Group dropped their price objective on Axon Enterprise from $610.00 to $570.00 and set a "neutral" rating for the company in a research note on Wednesday, February 25th. Royal Bank Of Canada dropped their price objective on Axon Enterprise from $860.00 to $735.00 and set an "outperform" rating for the company in a research note on Wednesday, February 25th. TD Cowen dropped their price objective on Axon Enterprise from $950.00 to $825.00 and set a "buy" rating for the company in a research note on Wednesday. Morgan Stanley dropped their price objective on Axon Enterprise from $713.00 to $675.00 and set an "overweight" rating for the company in a research note on Wednesday, February 25th. Finally, Northcoast Research upgraded Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 price objective for the company in a research note on Tuesday, January 6th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus target price of $755.88.

Insider Buying and Selling

In other news, Director Jeri Williams sold 157 shares of the firm's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director directly owned 1,159 shares in the company, valued at approximately $567,910. This trade represents a 11.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the sale, the chief executive officer owned 3,090,997 shares of the company's stock, valued at approximately $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 in the last 90 days. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.